Evaluation of imaging differences in different molecular subtypes of hepatocellular adenoma

Abstract

Abstract: Objective To analyze the differences in imaging manifestations of different molecular subtypes of hepatocellular adenoma (HCA). Methods From January 2015 to December 2022, 100 HCA patients diagnosed and treated in our hospital were divided into inflammatory HCA (I-HCA, 62 cases) and liver cell nuclear factor 1 based on their molecular subtypes α Deactivated HCA (H-HCA, 22 cases) β- Chain protein activated HCA (B-HCA, 9 cases), unclassified HCA (U-HCA, 7 cases). Provide patients with ultrasound and magnetic resonance imaging examinations to analyze the differences in imaging manifestations among patients with different molecular subtypes. Results The ultrasound characteristics showed that there was a statistically significant difference in comparing the internal echoes, blood flow signals, delayed phase enhancement intensity, and subcapsular enhanced vascular shadows of different molecular subtypes of HCA (P<0.05). After magnetic resonance imaging examination, there was a statistically significant difference in T2WI signals, enhancement methods, and fatty liver among different molecular subtypes of HCA (P<0.05). Conclusion The ultrasound and magnetic resonance imaging manifestations of different molecular subtypes of HCA vary. Among them, I-HCA mainly presents as low echo, semi circular or circular blood flow signal, low enhancement in the delay phase, enhancement of blood vessels under the capsule, high signal on T2WI, continuous enhancement, and accompanied by fatty liver. H-HCA is characterized by high echo and overall high enhancement in the arterial phase, while B-HCA and U-HCA have fewer cases and no significant specificity in imaging manifestations, It needs to be improved in future research.

Key words: Hepatocellular adenoma, Molecular subtypes, Imaging manifestations

LIAO Zhong-yang, LI Hang, CHEN Yong-song. Evaluation of imaging differences in different molecular subtypes of hepatocellular adenoma[J]. Chinese Hepatolgy, 2024, 29(8): 960-964.

References 16

[1]	郭敬强, 张坤, 林巧妹, 等. 四例肝细胞腺瘤影像学和病理特征分析[J]. 肝胆胰外科杂志, 2022, 34(4): 237-240.
[2]	Chen K, Dong Y, Zhang W, et al. Analysis of contrast-enhanced ultrasound features of hepatocellular adenoma according to different pathological molecular classifications[J]. Clin Hemorheol Microcirc, 2020, 76(3): 391-403.
[3]	杨阮阮, 李锦忠, 龚晓兵. 基于DNA甲基化的分子亚型可预测肝细胞癌患者的预后[J]. 海南医学, 2020, 31(22): 2870-2876.
[4]	陈凯玲, 罗荣奎, 朱宇莉, 等. 肝细胞腺瘤超声造影与增强CT表现对比分析[J]. 中国临床医学, 2022, 29(2): 247-254.
[5]	刘贯清, 杨姗, 龚良庚, 等. 肝细胞腺瘤亚型MRI影像分析[J]. 临床放射学杂志, 2021, 40(3): 499-504.
[6]	周烁, 张树庚, 宋瑞鹏, 等. 肝细胞腺瘤癌变分子机制的研究进展[J]. 中华肝胆外科杂志, 2019, 25(10): 794-796.
[7]	Herman P, Fonseca GM, Kruger JAP, et al. Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons’ Perspective[J]. J Gastrointest Surg, 2021, 25(6): 1494-1502.
[8]	王鹏雁, 邵汇琳, 班新超, 等. 基于免疫组化的肝细胞腺瘤分型及临床病理学分析[J]. 中华肝胆外科杂志, 2019, 25(7): 509-512.
[9]	陈凯玲, 张炜彬, 毛枫, 等. 超声造影诊断炎症型肝细胞腺瘤的临床应用[J]. 中华超声影像学杂志, 2021, 30(1): 48-53.
[10]	陈凯玲, 朱宇莉, 董怡, 等. 肝细胞腺瘤常规超声及超声造影特征分析:单中心回顾性研究[J]. 复旦学报(医学版), 2022, 49(2): 180-188.
[11]	吴加满, 黄晓辉, 项剑瑜. 肝细胞腺瘤磁共振成像影像特征分析[J]. 中华肝胆外科杂志, 2020, 26(7): 535-538.
[12]	吴德生, 曾祥龙, 冯林, 等. 不同分子亚型肝细胞腺瘤MRI特征分析[J]. 实用放射学杂志, 2023, 39(4): 600-603.
[13]	Bise S, Frulio N, Hocquelet A, et al. New MRI features improve subtype classification of hepatocellular adenoma[J]. Eur Radiol, 2019, 29(5): 2436-2447.
[14]	方艺, 周国锋, 徐进, 等. 肝腺瘤四种亚型的MRI表现[J]. 南通大学学报(医学版), 2021, 41(6): 545-548.
[15]	Kim TH, Woo S, Ebrahimzadeh S, et al. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2023, 220(1): 28-38.
[16]	汪禾青, 杨春, 盛若凡, 等. 肝脏局灶性结节性增生与炎症型肝细胞腺瘤的MRI表现和鉴别诊断[J]. 中华肝胆外科杂志, 2018, 24(6): 361-366.